📊 NSPR Key Takeaways
Is InspireMD, Inc. (NSPR) a Good Investment?
InspireMD is a deeply unprofitable medical device company with severe operational challenges, burning cash at an unsustainable rate despite modest revenue growth. The company lost $48.8M on $9M in revenue, generating negative free cash flow of -$36.8M, which will rapidly deplete the $8.9M cash position without significant operational improvements or capital infusion. While balance sheet leverage is manageable and current liquidity ratios appear healthy, these assets cannot offset the fundamental inability to generate profits or positive cash flow.
Top-line growth is improving, but the business remains far from profitability with operating and net margins worse than -500% and ROE/ROA deeply negative. Cash burn is severe relative to the $8.94M cash balance, implying a short runway and likely need for external financing despite low leverage and strong current ratios. Until gross margin expands materially and operating expenses are contained, fundamentals remain unattractive.
Why Buy InspireMD, Inc. Stock? NSPR Key Strengths
- Revenue growth of 28.1% YoY indicates market traction in medical device segment
- Low debt-to-equity ratio of 0.09x provides financial flexibility and minimal leverage risk
- Positive gross margin of 29.5% suggests product-level economics are viable
- Strong liquidity (current 5.74x, quick 5.42x)
- Low leverage (Debt/Equity 0.09x)
- Solid revenue growth (+28.1% YoY)
NSPR Stock Risks: InspireMD, Inc. Investment Risks
- Operating cash burn of $35.1M annually with only $8.9M cash on hand results in critical runway of approximately 3 months
- Extreme operating losses of -$49.6M on $9M revenue indicate severe operational inefficiencies or non-capitalized R&D/regulatory costs
- Negative free cash flow of -$36.8M unsustainable; company will require dilutive financing or asset sales to survive
- Massive gap between gross profit ($2.6M) and operating income (-$49.6M) suggests high fixed costs, R&D, or SG&A burden
- Extreme unprofitability (operating margin -552.6%, ROE -88.4%)
- High cash burn vs cash ($-36.77M FCF vs $8.94M cash)
- Potential dilution/financing need given negative interest coverage
Key Metrics to Watch
- Quarterly operating cash flow trajectory - must reach positive territory within 2-3 quarters
- Revenue growth sustainability and gross margin maintenance through scale
- Operating expense reduction and path to profitability timeline
- Cash position and runway remaining before liquidity crisis
- Operating cash flow (quarterly)
- Gross margin trend
InspireMD, Inc. (NSPR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.74x current ratio provides a solid financial cushion.
NSPR Profit Margin, ROE & Profitability Analysis
NSPR vs Healthcare Sector: How InspireMD, Inc. Compares
How InspireMD, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is InspireMD, Inc. Stock Overvalued? NSPR Valuation Analysis 2026
Based on fundamental analysis, InspireMD, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
InspireMD, Inc. Balance Sheet: NSPR Debt, Cash & Liquidity
NSPR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: InspireMD, Inc.'s revenue has grown significantly by 100% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.76 indicates the company is currently unprofitable.
NSPR Revenue Growth, EPS Growth & YoY Performance
NSPR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.8M | -$7.9M | $-0.16 |
| Q2 2025 | $1.7M | -$7.9M | $-0.22 |
| Q1 2025 | $1.5M | -$7.0M | $-0.21 |
| Q3 2024 | $1.6M | -$5.2M | $-0.15 |
| Q2 2024 | $1.6M | -$5.1M | $-0.22 |
| Q1 2024 | $1.2M | -$4.3M | $-0.21 |
| Q3 2023 | $1.4M | -$4.5M | $-0.15 |
| Q2 2023 | $1.5M | -$4.6M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
InspireMD, Inc. Dividends, Buybacks & Capital Allocation
NSPR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for InspireMD, Inc. (CIK: 0001433607)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NSPR
What is the AI rating for NSPR?
InspireMD, Inc. (NSPR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NSPR's key strengths?
Claude: Revenue growth of 28.1% YoY indicates market traction in medical device segment. Low debt-to-equity ratio of 0.09x provides financial flexibility and minimal leverage risk. ChatGPT: Strong liquidity (current 5.74x, quick 5.42x). Low leverage (Debt/Equity 0.09x).
What are the risks of investing in NSPR?
Claude: Operating cash burn of $35.1M annually with only $8.9M cash on hand results in critical runway of approximately 3 months. Extreme operating losses of -$49.6M on $9M revenue indicate severe operational inefficiencies or non-capitalized R&D/regulatory costs. ChatGPT: Extreme unprofitability (operating margin -552.6%, ROE -88.4%). High cash burn vs cash ($-36.77M FCF vs $8.94M cash).
What is NSPR's revenue and growth?
InspireMD, Inc. reported revenue of $9.0M.
Does NSPR pay dividends?
InspireMD, Inc. does not currently pay dividends.
Where can I find NSPR SEC filings?
Official SEC filings for InspireMD, Inc. (CIK: 0001433607) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NSPR's EPS?
InspireMD, Inc. has a diluted EPS of $-0.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NSPR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, InspireMD, Inc. has a STRONG SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NSPR stock overvalued or undervalued?
Valuation metrics for NSPR: ROE of -88.4% (sector avg: 15%), net margin of -543.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NSPR stock in 2026?
Our dual AI analysis gives InspireMD, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NSPR's free cash flow?
InspireMD, Inc.'s operating cash flow is $-35.1M, with capital expenditures of $1.7M. FCF margin is -409.5%.
How does NSPR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -543.3% (avg: 12%), ROE -88.4% (avg: 15%), current ratio 5.74 (avg: 2).